MVIRMedivir ABMVIR info
$0.32info-3.78%24h
Global rank
Market cap$18.01M
Change 7d-0.28%
YTD Performance13.09%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Medivir AB (MVIR) Stock Overview

    Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

    MVIR Stock Information

    Symbol
    MVIR
    Address
    Lunastigen 5Huddinge, Sweden
    Founded
    -
    Trading hours
    -
    Website
    https://www.medivir.com
    Country
    πŸ‡ΈπŸ‡ͺ Sweden
    Phone Number
    46 8 54 68 31 00

    Medivir AB (MVIR) Price Chart

    -
    Value:-

    Medivir AB Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.3225046654467052
    N/A
    Market Cap
    $18.01M
    N/A
    Shares Outstanding
    55.83M
    N/A
    Employees
    10.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org